Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The efficacy of nilotinib treatment approaches in frontline CML

Timothy Hughes • 12 Jun 2022
EHA 2022
Chronic Myeloid Leukemia Leukemia Imatinib Nilotinib
TIDEL-II

Timothy Hughes, MD, FRACP, FRCPA, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia, shares some insights into a study comparing the use of nilotinib versus a nilotinib plus imatinib switch approach for the frontline treatment of chronic myeloid leukemia (CML). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Ad boards and research support from Novartis and Takeda.

More from Timothy Hughes

Selecting between TKIs for patients with CML
1:10
Selecting between TKIs for patients with CML
Timothy Hughes • 11 Jun 2026
Biological barriers preventing patients from achieving durable remission in CML
1:05
Biological barriers preventing patients from achieving durable remission in CML
Timothy Hughes • 11 Jun 2026
Week 144 analysis of the ASC4FIRST trial: asciminib in newly diagnosed chronic phase CML
1:20
Week 144 analysis of the ASC4FIRST trial: asciminib in newly diagnosed chronic phase CML
Timothy Hughes • 11 Jun 2026
Update on the ASCEND-CML study investigating frontline asciminib for patients with CML
0:56
Update on the ASCEND-CML study investigating frontline asciminib for patients with CML
Timothy Hughes • 7 Dec 2024

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals